DRIVEN

Our lead program, THB-001, is a potent and highly selective, oral small molecule inhibitor of KIT, a master regulator of mast cell function and survival. Mast cells have long been known to be a central driver of allergic and inflammatory processes. By inhibiting KIT, THB-001 is expected to inactivate and deplete mast cells, providing the potential for broad symptomatic relief across a range of inflammatory diseases.

With “pipeline-in-a-product” potential, THB-001 is entering Phase 1b clinical trials for chronic inducible urticaria, a dermatologic disease driven by mast cell activation, resulting in red, itchy, painful wheals or hives that can severely impact a patient’s quality of life.